PMID- 22088520
OWN - NLM
STAT- MEDLINE
DCOM- 20120504
LR  - 20181201
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 124
IP  - 20
DP  - 2011 Oct
TI  - Comparison of tirofiban combined with dalteparin or unfractionated heparin in 
      primary percutaneous coronary intervention of acute ST-segment elevation 
      myocardial infarction patients.
PG  - 3275-80
AB  - BACKGROUND: Primary percutaneous coronary intervention (PCI) is the best 
      treatment of choice for acute ST segment elevation myocardial infarction (STEMI). 
      This study aimed to determine the clinical outcomes of tirofiban combined with 
      the low molecular weight heparin (LMWH), dalteparin, in primary PCI patients with 
      acute STEMI. METHODS: From February 2006 to July 2006, a total of 120 patients 
      with STEMI treated with primary PCI were randomised to 2 groups: unfractionated 
      heparin (UFH) with tirofiban (group I: 60 patients, (61.2 +/- 9.5) years), and 
      dalteparin with tirofiban (group II: 60 patients, (60.5 +/- 10.1) years). Major 
      adverse cardiac events (MACE) during hospitalization and at 4 years after PCI 
      were examined. Bleeding complications during hospitalization were also examined. 
      RESULTS: There were no significant differences in sex, mean age, risk factors, 
      past history, inflammatory marker, or echocardiography between the 2 groups. In 
      terms of the target vessel and vascular complexity, there were no significant 
      differences between the 2 groups. During the first 7 days, emergent 
      revascularization occurred only in 1 patient (1.7%) in group I. Acute myocardial 
      infarction (AMI) occurred in 1 (1.7%) patient in group I and in 1 (1.7%) in group 
      II. Three (5.0%) patients in group I and 1 (1.7%) in group II died. Total 
      in-hospital MACE during the first 7 days was 4 (6.7%) in group I and 2 (3.3%) in 
      group II. Bleeding complications were observed in 10 patients (16.7%) in group I 
      and in 4 patients (6.7%) in group II, however, the difference was not 
      statistically significant. No significant intracranial bleeding was observed in 
      either group. Four years after PCI, death occurred in 5 (8.3%) patients in group 
      I and in 4 (6.7%) in group II. MACE occurred in 12 (20.0%) patients in group I 
      and in 10 (16.7%) patients in group II. CONCLUSIONS: Dalteparin was effective and 
      safe in primary PCI of STEMI patients and combined dalteparin with tirofiban was 
      effective and safe without significant bleeding complications compared with UFH. 
      Although there was no statistically significant difference, LMWH decreased the 
      bleeding complications compared with UFH.
FAU - Li, Wei-Ming
AU  - Li WM
AD  - The Heart Center, Beijing Chao Yang Hospital, Capital Medical University, Beijing 
      100020, China.
FAU - Yang, Xin-Chun
AU  - Yang XC
FAU - Wang, Le-Feng
AU  - Wang LF
FAU - Ge, Yong-Gui
AU  - Ge YG
FAU - Wang, Hong-Shi
AU  - Wang HS
FAU - Xu, Li
AU  - Xu L
FAU - Ni, Zhu-Hua
AU  - Ni ZH
FAU - Zhang, Da-Peng
AU  - Zhang DP
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (Anticoagulants)
RN  - 42HK56048U (Tyrosine)
RN  - 9005-49-6 (Heparin)
RN  - GGX234SI5H (Tirofiban)
RN  - S79O08V79F (Dalteparin)
SB  - IM
MH  - Aged
MH  - *Angioplasty, Balloon, Coronary
MH  - Anticoagulants/*therapeutic use
MH  - Dalteparin/administration & dosage/*therapeutic use
MH  - Female
MH  - Heparin/administration & dosage/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy/*therapy
MH  - Tirofiban
MH  - Treatment Outcome
MH  - Tyrosine/*analogs & derivatives/therapeutic use
EDAT- 2011/11/18 06:00
MHDA- 2012/05/05 06:00
CRDT- 2011/11/18 06:00
PHST- 2011/11/18 06:00 [entrez]
PHST- 2011/11/18 06:00 [pubmed]
PHST- 2012/05/05 06:00 [medline]
PST - ppublish
SO  - Chin Med J (Engl). 2011 Oct;124(20):3275-80.